Thorasys raises $1.3 million to develop a new method of measuring lung function

Montreal-based Thorasys, which is developing products for the diagnosis of lung diseases, has raised $1.3 million in funding from Anges Quebec.

“We had to find credible financial partners able to support us at this new stage of our development. Anges Québec’s support for our board of directors and our financing efforts will enable us to get our solutions to market faster and meet the growing need for our technology,” said Thorasys president and CEO Thomas Schuessler.

The company will use the funding to commercialize its tremoFlo C-100 Airwave Oscillometry System (AOS), which uses a Forced Oscillation Technique to measures lung function by superimposing a gentle multi-frequency airwave onto the patient’s respiratory airflow.

“The expertise developed by Thorasys over the years and the quality of the tremoFlo™ C-100 Airwave Oscillometry System were key factors in our decision to support Thomas and his team,” said Marcel Larochelle and Xavier Harland, two angel investors. “We’re happy our contribution will help Thorasys pursue its successful growth.”